Cholesterol emboli to the kidney: An immunoperoxidase study

Pathology

Volumn 33, Issue 2, 2001, Pages 157-162

  Wongprasartsuk, Sarin ^a   Finlay, Moira ^b   Perry, Greg J ^a  

^a ALFRED HOSPITAL   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Atheroma; Cholesterol emboli; Myofibroblast

Indexed keywords

EOSIN; HEMATOXYLIN; PEROXIDASE;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL COUNT; CELL INFILTRATION; CELL INTERACTION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FAT EMBOLISM; FEMALE; GRANULATION TISSUE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; KIDNEY FAILURE; MACROPHAGE; MALE; MYOFIBROBLAST; NEUTROPHIL; RISK FACTOR; SMOOTH MUSCLE FIBER; T LYMPHOCYTE;

EID: 0035019998     PISSN: 00313025     EISSN: None     Source Type: Journal    
DOI: 10.1080/00313020124460     Document Type: Article

References (35)

1. Harrington JT, Sommers SC, Kassirer JP. Atheromatous emboli with progressive renal failure: renal arteriography as a probable inciting factor. Ann Int Med 1968; 68: 152-60.
2. Gaines PA, Cumberland DC, Kennedy A, Welsh CL, Moorhead P, Rutley MS. Cholesterol embolization: a lethal complication of vascular catheterisation. Lancet 1988; 1 (8578): 168-70.
3. Drost H, Buis B, Haan D, Hillers JA. Cholesterol embolism as a complication of left heart catheterisation: report of seven cases. Br Heart J 1984; 52: 339-42.
4. Ramirez G, O'Niell WM, Lambert R, Bloomer HA. Cholesterol embolization: a complication of angiography. Arch Intern Med 1978; 138: 1430-42.
5. Thadhani R, Camargo C, Xavier M, Fang L, Bazari H. Atheroembolic renal failure after invasive procedures: natural history based on 52 histologically proven cases. Medicine 1995; 74: 350-8.
6. Weitz Z, Gafter U, Chagnac A, Levi J. Cholesterol emboli in atherosclerotic patients: reports of four cases occurring spontaneously or complicating angioplasty and aortorenal bypass. J Am Geriatr Soc 1987; 35: 357-9.
7. Fraser I, Ihle B, Kincaid-Smith P. Renal failure due to cholesterol emboli. Aust N Z J Med 1991; 21: 418-21.
8. Florey CM. Arterial occlusions produced by emboli from eroded aortic atheromatous plaques. Am J Pathol 1945; 21: 549-65.
9. Moolenaar W, Lamers C. Cholesterol crystal embolization in the Netherlands: a review of 842 cases filed in the National Pathology Information System from 1973 through 1994. Arch Intern Med 1996; 156: 653-7.
10. Cross SS. How common is cholesterol embolism? J Clin Pathol 1991; 44: 859-61.
11. Lie J. Cholesterol atheromatous embolism: the great masquerader revisited. Pathol Annu 1992; 27 pt 2: 17-50.
12. Jones DB, Iannaccone PM. Atheromatous emboli in renal biopsies. Am J Pathol 1975; 78: 261-76.
13. Scolari F, Bracchi M, Valzorio B, et al. Cholesterol atheromatous embolism: an increasingly recognized cause of acute renal failure. Nephrol Dial Transplant 1996; 11: 1607-12.
14. Stratford N, Britten K, Gallagher P. Inflammatory infiltrates in human coronary atherosclerosis. Atherosclerosis 1986; 59: 271-6.
15. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986; 6: 131-8.
16. Kealy WF. Atheroembolism. J Clin Pathol 1978; 31: 984-9.
17. Hammerschmidt DE, Greenberg CS, Yamada O, Craddock PR, Jacob HS. Cholesterol and atheroma lipids activate complement and stimulate granulocytes. J Lab Clin Med 1981; 98: 68-77.
18. Vidt D. Cholesterol emboli: a common cause of renal failure. Ann Rev Med 1997; 48: 375-85.
19. Ho SW-C, Thatcher GN, Matz LR. Reversible renal failure due to renal cholesterol embolism. Aust N Z J Med 1982; 12: 531-3.
20. Cosio FG, Zager RA, Sharma HM. Atheroembolic renal disease causes hypocomplementaemia. Lancet 1985; 2(8447): 118-21.
21. Kasinath BS, Corwin HL, Bidani AK, Korbet SM, Schwartz MM, Lewis EJ. Eosinophilia in the diagnosis of atheroembolic renal disease. Am J Nephrol 1987; 7: 173-7.
22. Zhang S, Mohammed Q, Burbidge A, Morland CM, Roche WR. Cell cultures from bronchial subepithelial myofibroblasts enhance eosinophil survival in vitro. Eur Respir J 1996; 9: 1839-48.
23. Gabbiani G. The cellular derivation and life span of the myofibroblast. Pathol Res Pract 1996; 192: 708-11.
24. Gressner AM. Transdifferentiation of hepatic stellate cells (Ito cells) to myofibroblasts: a key event in hepatic fibrogenesis. Kidney Int 1996; 49 (Suppl 54): S39-45.
25. Gressner AM, Polzar B, Lahme B, Mannherz H. Induction of rat parenchymal cell apoptosis by hepatic myofibroblasts via transforming growth factor β. Hepatotogy 1996; 23: 571-81.
26. Lee KS, Buck M, Houglum K, Chojkier M. Molecular events during myofibroblast activation: is there specificity? Hepatology 1996; 24: 742-3.
27. Maxwell PH, Ferguson DJP, Nicholls LG, Johnson MH, Ratcliffe PJ. The interstitial response to renal injury: fibroblast-like cells show phenotypic changes and have reduced potential for erythropoietin gene expression. Kidney Int 1997; 52: 715-24.
28. Muchaneta-Kubara EC, El Nahas AM. Myofibroblast phenotypes expression in experimental renal scarring. Nephrol Dial Transplant 1997; 12: 904-15.
29. Pedadagos E, Hewitson T, Fraser I, Nicholls K, Becker G. Myofibroblasts and arteriolar sclerosis in human diabetic nephropathy. Am J Kidney Dis 1997; 29: 912-6.
30. Shi Y, O'Brien JE, Faird A, Zalewski A. Transforming growth factor β1 expression and myofibroblast formation during arterial repair. Arterioscler Thromb Vasc Biol 1996; 16: 1298-305.
31. Sternberg S. Histology for Pathologist. New York: Raven Press, 1992; Chapter 5, Myofibroblast.
32. Greenberg A, Bastacky S, Iqbal A, Borochovitz D, Johnson J. Focal segmental glomerulosclerosis associated with nephrotic syndrome in cholesterol atheroembolism: clinicopathological correlations. Am J Kidney Dis 1997; 29: 334-44.
33. Mannesse CK, Blankenstijn PJ, Man In'T Veld AJ, Schalekemp MADH. Renal failure and cholesterol embolization: a report of 4 surviving cases and a review of the literature. Clin Nephrol 1991; 36: 240-5.
34. Ben-Chitrit S, Korzets Z, Hershkovitz R, Bemheim J, Schneider M, Bemheim J. Cholesterol embolization syndrome following thrombolytic therapy with streptokinase and tissue plasminogen activator. Nephrol Dial Transplant 1994; 9: 428-30.
35. Keen R, McCarthy W, Shireman P, et al. Surgical management of atheroembolization. J Vasc Surg 1995; 21: 773-81.